Pay in 4 interest-free payments of $7.29 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
It is a GLP-1 GIP agonist weight loss research drug
GLP-1 cannot be injected into everyone
What PIONEER-1 Actually Changes in Clinical Practice At a glance | Field | Detail | |---|---| | Trial name | PIONEER-1 | | N | 703 | | Population | Adults with T2D on diet/exercise alone, mean A1C ~8.0% | | Intervention | Oral semaglutide 3 mg, 7 mg, or 14 mg once daily | | Comparator | Placebo | | Duration | 26 weeks | | Primary endpoint | Change in A1C from baseline | | Key result | 14 mg arm: 1.5% A1C (estimand: treatment policy)
She was not involved in the study but is on Novo Nordisks scientific advisory board
Compounding pharmacies typically prepare versions of approved medications that are not widely available, but they can also fill in gaps in supply
The compound is often characterized as a melanocortin-oriented peptide
US$ 22.34
US$ 29.17
US$ 22.69
US$ 20.59
US$ 24.88
US$ 24.11
US$ 20.38
![Moritte of the Frost (Showcase) [Kaldheim] SPA Pirohemia](https://cdn.shopify.com/s/files/1/0268/5285/1798/products/4fdf8cf6-5a4c-54e6-b18a-5097593cff0a.jpg?v=1662476657)